SCHEMBL1106708

SCHEMBL1106708

C=C1OCC1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14997291 0.73
SCHEMBL20158793 0.73
SCHEMBL2376391 0.69
SCHEMBL3944987 0.69
SCHEMBL15172114 0.69
SCHEMBL3947301 0.69
SCHEMBL14559791 0.68
SCHEMBL25472223 0.67
SCHEMBL19943246 0.67
SCHEMBL576623 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0446925-B1 Process for the preparation of beta-resorcylic acid derivatives CONSORTIUM ELEKTROCHEM IND (DE) 1995-06-21 EP claimed
US-5171878-A Reacting a diketene with a beta-keto ester in presence of alkaline earth compound; perfumes CONSORTIUM FOR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1992-12-15 US claimed
US-11744816-B2 Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease ESPERION THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230210800-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS INC (US) 2023-07-06 US disclosed
US-20180133177-A1 Treatment of NASH with Gemcabene NEUROBO PHARMACEUTICALS, INC. 2018-05-17 US disclosed
US-20180064671-A1 Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease GLAS AMERICAS LLC 2018-03-08 US disclosed
US-9855240-B2 Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2018-01-02 US disclosed
US-9849104-B2 Treatment of NASH with gemcabene GEMPHIRE THERAPEUTICS INC. (US) 2017-12-26 US disclosed
US-20170349516-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-20170172955-A1 Treatment of Mixed Dyslipidemia NEUROBO PHARMACEUTICALS, INC. 2017-06-22 US disclosed
US-20170172954-A1 Treatment of NASH with Gemcabene NEUROBO PHARMACEUTICALS, INC. 2017-06-22 US disclosed
CN-101115488-B Pharmaceutical use of atraric acid LOHMANN THERAPIE SYST LTS 2011-03-30 CN disclosed
US-20110003860-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2011-01-06 US disclosed
US-20090143466-A1 Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2009-06-04 US disclosed
EP-1979309-A2 PROCESS FOR THE PREPARATION OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONIC ACID AMIDES AND INTERMEDIATES USED THEREIN Boehringer Ingelheim International GmbH (DE) 2008-10-15 EP disclosed
US-7335689-B2 for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy ESPERION THERAPEUTICS, INC. (US) 2008-02-26 US disclosed
CN-101115488-A Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the deritives thereof for the treatment of benign prostate hyperplasia, prostate carcinoma and spinobulbar LOHMANN THERAPIE SYST LTS (DE) 2008-01-30 CN disclosed
WO-2007084882-A2 PROCESS FOR THE PREPARATION OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONIC ACID AMIDES AND INTERMEDIATES USED THEREIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-26 WO disclosed
US-20070173517-A1 Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides WIRTH THOMAS 2007-07-26 US disclosed
US-5171878-A Reacting a diketene with a beta-keto ester in presence of alkaline earth compound; perfumes CONSORTIUM FOR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1992-12-15 US disclosed